Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

PRECLINICAL WORST-CASE TESTING OF A NOVEL VITAMIN-DOPED HXLPE

Australian Orthopaedic Association and New Zealand Orthopaedic Association (AOA/NZOA) - Combined Annual Scientific Meeting



Abstract

The introduction of a new implant material is not without risk. A series of worst-case scenarios were developed and tested accordingly to answer questions such as: what will happen if the implant is not placed in a good orientation? What will happen to the material after a long implantation time, e.g. 20 or more years?

To reach a higher level of safety, a new approach for the preclinical testing has been taken. The vitamys® material (a novel vitamin-doped HXLPE) followed a severe pre-clinical testing protocol, including mechanical, tribological and biocompatibility testing. The testing includes a comparison of vitamys® vs. standard-UHMWPE and other HXLPE after accelerated ageing for periods equivalent to 20 and 40 years in-vivo. Hip simulator testing was done at inclination angles from 35° to 65° to assess the “forgiveness” of the material for mal-orientation.

Comparing the test results to published data, it becomes evident that the vitamin addition and the sequence of the manufacturing steps both have a significant effect of the resulting mechanical, ageing and wear properties. In contrast to UHMWPE or HXLPE without antioxidant, the vitamys material behaves in a very “forgiving” manner: Hip simulator testing of vitamys at high inclination angles and even with severely aged material revealed no increase of wear rates. The vitamys material was first introduced in a monoblock polyethylene cup with a thin Ti-particle coating, the RM-Pressfit vitamys® acetabular cup (Mathys Ltd Bettlach, Switzerland). Its first implantation occurred in Sept. 2009. Since then, a total of nearly 500 implantations have been documented in a prospective multi-centre clinical study involving 11 clinics in 5 countries (CH, DE, FR, NL and NZ).

Based on the pre-clinical testing and its first clinical experience, we have reason to believe that the RM-Pressfit vitamys® possesses interesting and unique features such as high elasticity (no stress-shielding), high ageing and wear resistance combined with clinically proven biological anchorage – making it theoretically suitable for a whole range of patients, including the young and active.